Top

Published in:

01-10-2014 | Original Paper

Prognostic impact of the serum heart-type fatty acid-binding protein (H-FABP) levels in patients admitted to the non-surgical intensive care unit

Authors: Akihiro Shirakabe, Nobuaki Kobayashi, Noritake Hata, Masanori Yamamoto, Takuro Shinada, Kazunori Tomita, Masafumi Tsurumi, Masato Matsushita, Hirotake Okazaki, Yoshiya Yamamoto, Shinya Yokoyama, Kuniya Asai, Wataru Shimizu

Published in: Clinical Research in Cardiology | Issue 10/2014

Abstract

Background

Biomarkers predicting adverse outcomes in non-surgical intensive care patients have not been reported.

Methods and results

Data for 1,006 emergency department patients were prospectively analyzed. The serum heart-type fatty acid-binding protein (s-H-FABP) level was measured within 10 min of admission. The patients were assigned to intensive care (n = 835) or other departments (n = 171). The intensive care patients were divided into survivors (n = 745) and non-survivors (n = 90) according to the in-hospital mortality and assigned to four groups according to the quartiles of s-H-FABP (Q1, Q2, Q3 and Q4). The s-H-FABP levels were significantly higher in the intensive care patients (12.7 [6.1–38.8] ng/ml versus 5.3 [3.1–9.4] ng/ml) and in the non-survivors (44.9 [23.2–87.6] ng/ml versus 11.5 [5.6–32.6] ng/ml). A Kaplan–Meier curve showed a significantly higher survival rate in Q3 than in Q1 and Q2 and in Q4 than in the other groups. The multivariate Cox regression model identified Q3 (HR 4.646, 95 % CI 1.526–14.146) and Q4 (HR 9.483, 95 % CI 3.152–28.525) as independent predictors of 90-day mortality. The sensitivity and specificity of H-FABP for in-hospital mortality were 81.1 and 66.0 % (AUC 0.775) at 20.95 ng/ml. The in-hospitality rate was significantly higher in the high s-H-FABP patients than in the low s-H-FABP patients in each etiology group.

Conclusions

The s-H-FABP level is an effective biomarker for risk stratification in non-surgical intensive care patients.

Inoue K, Suwa S, Ohta H, Itoh S, Maruyama S, Masuda N, Sugita M, Daida H (2011) Heart fatty acid-binding protein offers similar diagnostic performance to high-sensitivity troponin T in emergency room patients presenting with chest pain. Circ J 75:2813–2820PubMedCrossRef

Seino Y, Ogawa A, Yamashita T, Fukushima M, Ogata K, Fukumoto H, Takano T (2004) Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 6:295–300PubMedCrossRef

Normann J, Mueller M, Biener M, Vafaie M, Katus HA, Giannitsis E (2012) Effect of older age on diagnostic and prognostic performance of high-sensitivity troponin T in patients presenting to an emergency department. Am Heart J 164:698–705PubMedCrossRef

Yamamoto T, Yamamoto A, Watanabe M, Matsuo T, Yamazaki N, Kataoka M, Terada H, Shinohara Y (2009) Classification of FABP isoforms and tissues based on quantitative evaluation of transcript levels of these isoforms in various rat tissues. Biotechnol Lett 31:1695–1701PubMedCrossRef

Ecollan P, Collet JP, Boon G, Tanguy ML, Fievet ML, Haas R, Bertho N, Siami S, Hubert JC, Coriat P, Montalescot G (2007) Pre-hospital detection of acute myocardial infarction with ultra-rapid human fatty acid-binding protein (H-FABP) immunoassay. Int J Cardiol 119:349–354PubMedCrossRef

Seino Y, Tomita Y, Takano T, Ohbayashi K, Tokyo Rapid-Test Office Cardiologists (Tokyo-ROC) Study (2004) Office cardiologists cooperative study on whole blood rapid panel tests in patients with suspicious acute myocardial infarction: comparison between heart-type fatty acid-binding protein and troponin T tests. Circ J 68:144–148PubMedCrossRef

Reiter M, Twerenbold R, Reichlin T, Mueller M, Hoeller R, Moehring B, Haaf P, Wildi K, Merk S, Bernhard D, Mueller CZ, Freese M, Freidank H, Campodarve Botet I, Mueller C (2013) Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction. Heart 99:708–714PubMedCrossRef

Goto T, Takase H, Toriyama T, Sugiura T, Sato K, Ueda R, Dohi Y (2003) Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart 89:1303–1307PubMedCentralPubMedCrossRef

Arimoto T, Takeishi Y, Shiga R, Fukui A, Tachibana H, Nozaki N, Hirono O, Nitobe J, Miyamoto T, Hoit BD, Kubota I (2005) Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. J Card Fail 11:56–60PubMedCrossRef

10.

Setsuta K, Seino Y, Kitahara Y, Arau M, Ohbayashi T, Takano T, Mizuno K (2008) Elevated levels of both cardiomyocyte membrane and myofibril damage markers predict adverse outcomes in patients with chronic heart failure. Circ J 72:569–574PubMedCrossRef

11.

Niizeki T, Takeishi Y, Arimoto T, Takabatake N, Nozaki N, Hirono O, Watanabe T, Nitobe J, Harada M, Suzuki S, Koyama Y, Kitahara T, Sasaki T, Kubota I (2007) Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail 13:120–127PubMedCrossRef

12.

Matsumoto S, Nakatani D, Sakata Y, Suna S, Shimizu M, Usami M, Hara M, Sumitsuji S, Nanto S, Sasaki T, Hamasaki T, Sato H, Hori M, Komuro I, Osaka Acute Coronary Insufficiency Study (OACIS) Group (2013) Elevated serum heart-type fatty acid-binding protein in the convalescent stage predicts long-term outcome in patients surviving acute myocardial infarction. Circ J 77:1026–1032PubMedCrossRef

13.

Reynolds T, Cecconi M, Collinson P, Rhodes A, Grounds RM, Hamilton MA (2012) Raised serum cardiac troponin I concentrations predict hospital mortality in intensive care unit patients. Br J Anaesth 109:219–224PubMedCrossRef

14.

Yamashita T, Seino Y, Ogawa A, Ogata K, Fukushima M, Tanaka K, Mizuno K (2010) N-terminal pro-BNP is a novel biomarker for integrated cardio-renal burden and early risk stratification in patients admitted for cardiac emergency. J Cardiol 55:377–383PubMedCrossRef

15.

Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50:2357–2368PubMedCrossRef

16.

Kara K, Mahabadi AA, Geisel MH, Lehmann N, Kälsch H, Bauer M, Neumann T, Dragano N, Moebus S, Möhlenkamp S, Jöckel KH, Erbel R (2014) B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events-The Heinz Nixdorf Recall Study. Clin Res Cardiol 103:125–132PubMedCrossRef

17.

Tsutamoto T, Sakai H, Ishikawa C, Fujii M, Tanaka T, Yamamoto T, Takashima H, Ohnishi M, Wada A, Horie M (2007) Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure. Eur.J Heart Fail 9:667–673PubMedCrossRef

18.

Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L, International Working Group on Acute Heart Failure Syndromes (2005) Acute heart failure syndromes: current state and framework for future research. Circulation 112:3958–3968PubMedCrossRef

19.

Twerenbold R, Jaffe A, Reichlin T, Reiter M, Mueller C (2012) High-sensitive troponin T measurements: what do we gain and what are the challenges? Eur Heart J 33:579–586PubMedCrossRef

20.

Kobayashi N, Hata N, Kume N, Shinada T, Tomita K, Shirakabe A, Kitamura M, Nozaki A, Inami T, Seino Y, Mizuno K (2011) Soluble lectin-like oxidized LDL receptor-1 and high-sensitivity troponin T as diagnostic biomarkers for acute coronary syndrome. Improved values with combination usage in emergency rooms. Circ J 75:2862–2871PubMedCrossRef

21.

Baum H, Braun S, Gerhardt W, Gilson G, Hafner G, Muller-Bardorff M et al (1997) Multicenter evaluation of a second-generation assay for cardiac troponin T. Clin Chem 43:1877–1884PubMed

22.

Hallermayer K, Klenner D, Vogel R (1999) Use of recombinant human cardiac troponin T for standardization of third generation troponin T methods. Scand J Clin Lab Invest Suppl 230:128–131PubMedCrossRef

23.

Chorianopoulos E, Krumsdorf U, Geis N, Pleger ST, Giannitsis E, Katus HA, Bekeredjian R (2014) Preserved prognostic value of preinterventional troponin T levels despite successful TAVI in patients with severe aortic stenosis. Clin Res Cardiol 103:65–72PubMedCrossRef

24.

Viswanathan K, Kilcullen N, Morrell C, Thistlewaite SJ, Sinvanthan MU, Hassan TB, Barth JH, Hall AS (2010) Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected coronary syndrome who are troponin-nagative. J Am Coll Cardiol 55:2590–2598PubMedCrossRef

25.

Werdan K, Oelke A, Hettwer S, Nuding S, Bubel S, Hoke R, Russ M, Lautenschläger C, Mueller-Werdan U, Ebelt H (2011) Septic cardiomyopathy: hemodynamic quantification, occurrence, and prognostic implications. Clin Res Cardiol 100:661–668PubMedCrossRef

26.

Wilhelm J, Hettwer S, Schuermann M, Bagger S, Gerhardt F, Mundt S, Muschik S, Zimmermann J, Bubel S, Amoury M, Kloess T, Finke R, Loppnow H, Mueller-Werdan U, Ebelt H, Werdan K (2013) Severity of cardiac impairment in the early stage of community-acquired sepsis determines worse prognosis. Clin Res Cardiol 102:735–744PubMedCrossRef

27.

Landesberg G, Gilon D, Meroz Y, Georgieva M, Levin PD, Goodman S, Avidan A, Beeri R, Weissman C, Jaffe AS, Sprung CL (2012) Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J 33:895–903PubMedCentralPubMedCrossRef

28.

Seino Y, Ogata K, Takano T, Ishii J, Hishida H, Morita H, Takeshita H, Takagi Y, Sugiyama H, Tanaka T, Kutaura Y (2003) Use of a whole blood rapid panel test for heart-type fatty acid binding protein in patients with acute chest pain: comparison with rapid troponin T and myoglobrin tests. Am J Med 115:185–190PubMedCrossRef

29.

Setsuta K, Seino Y, Ogata T, Arao M, Miyatake Y, Takano T (2002) Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med 113:717–722PubMedCrossRef

30.

Hazui H, Negoro N, Nishimoto M, Muraoka H, Murai M, Takeshita H, Ohishi Y, Fukumoto H, Morita H, Hanafusa T (2005) Serum heart-type fatty acid-binding protein concentration positively correlates with the length of aortic dissection. Circ J 69:958–961PubMedCrossRef

31.

Dellas C, Puls M, Lankeit M, Schäfer K, Cuny M, Berner M, Hasenfuss G, Konstantinides S (2010) Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol 55:2150–2157PubMedCrossRef

32.

Boscheri A, Wunderlich C, Langer M, Schoen S, Wiedemann B, Stolte D, Elmer G, Barthel P, Strasser RH (2010) Correlation of heart-type acid-binding protein with mortality and echocardiogenic data in patients with pulmonary embolism at intermediate risk. Am Heart J 160:294–300PubMedCrossRef

33.

Jo YH, Kim K, Lee JH, Rhee JE, Lee JH, Kang KW, Rim KP, Hwang SS, Park HM (2012) Heart-type fatty acid-binding protein as a prognostic factor in patients with severe sepsis and septic shock. Am J Emerg Med 30:1749–1755PubMedCrossRef

34.

Tanaka T, Hirota Y, Sohmiya, Nishimura S, Kawamura K (1991) Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem 24:195–201PubMedCrossRef

35.

Yan GT, Lin J, Hao XH, Xue H, Zhang K, Wang LH (2009) Heart-type fatty acid-binding protein is a useful marker for organ dysfunction and leptin alleviate sepsis-induced organ injuries by restraining its tissue levels. Eur J Pharmacol 616:244–250PubMedCrossRef

36.

Glatz JF, Kleine AH, van Nieuwenhoven FA, Hermens WT, van Dieijen-Visser MP, van der Vusse GJ (1994) Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans. Br Heart J 71:135–140PubMedCentralPubMedCrossRef

Title: Prognostic impact of the serum heart-type fatty acid-binding protein (H-FABP) levels in patients admitted to the non-surgical intensive care unit
Authors: Akihiro Shirakabe
Nobuaki Kobayashi
Noritake Hata
Masanori Yamamoto
Takuro Shinada
Kazunori Tomita
Masafumi Tsurumi
Masato Matsushita
Hirotake Okazaki
Yoshiya Yamamoto
Shinya Yokoyama
Kuniya Asai
Wataru Shimizu
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 10/2014
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-014-0717-z

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Prognostic impact of the serum heart-type fatty acid-binding protein (H-FABP) levels in patients admitted to the non-surgical intensive care unit

Abstract

Background

Methods and results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods and results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2014

The remarkable effect of ivabradine in two adolescents with dilated cardiomyopathy

Multiplane two-dimensional strain echocardiography for segmental analysis of right ventricular mechanics

Ivabradine: a preliminary observation for a new terapeutic role in patients with multiple organ dysfunction syndrome

Feasibility of sheathless transfemoral aortic valve implantation in patients with small access vessel diameters

Correspondence on “Possible spontaneous PFO closure after thrombus trapped in PFO”, Antonia Schulz et al., Clin Res Cardiol 2014; 103:333-335

Case report: Recurrent non-ST-elevation myocardial infarction caused by a compression of left internal mammary artery graft by transvenous pacemaker lead

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page